Citadel Advisors
DRUG

Citadel Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Citadel Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.67M Buy
+66,533
New +$5.22M ﹤0.01% 4841
2025
Q4 		– Sell
-6,476
Closed -$393K – 12918
2025
Q3 		$393K Buy
+6,476
New +$251K ﹤0.01% 9709
2025
Q2 		– Sell
-6,885
Closed -$248K – 13069
2025
Q1 		$248K Buy
+6,885
New +$252K ﹤0.01% 10003
2024
Q2 		– Sell
-17,829
Closed -$21.4K – 14470
2024
Q1 		$21.4K Buy
+17,829
New +$31.3K ﹤0.01% 12968

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors's DRUG Position: Q2 2026 in Review

Citadel Advisors opened a new position in Bright Minds Biosciences (DRUG) in Q2 2026: 66,533 shares worth $4.67M. The stake represents ﹤0.01% of the portfolio and ranks #4841 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in DRUG as recently as Q3 2025.

Citadel Advisors first reported a position in DRUG in Q1 2024 and has held it in 4 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Citadel Advisors held 66,533 shares of Bright Minds Biosciences worth $4.67M as of Q2 2026.
  • Bright Minds Biosciences was a new Citadel Advisors position in Q2 2026.
  • Bright Minds Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4841 holding.
  • Citadel Advisors first reported a position in Bright Minds Biosciences in Q1 2024 and has held it in 4 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.